CHIOME BIOSCIENCE INC chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 14.65
Dividend & YieldN/A¥ (N/A)
Beta 1.05
Market capitalization 7.26B
Operating cash flow -1.23B
ESG Scores unknown

Company description

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery and Development Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development. The company also provides protein expression and purification services; stable cell line generation services for recombinant protein and antibody production; and antibody generation services using the ADLib system or B cell cloning techniques. Its product pipeline includes ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, neuroblastoma, etc.; CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, breast cancer (TNBC), etc.; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, colorectal cancer, etc.; and BMAA, an anti-semphorin3a antibody for treating central, immune/ inflammatory diseases, neurological disorder, and ophthalmic diseases. The company serves universities, research institutions, and pharmaceutical companies. It has a collaborative research agreement with Mologic Ltd. for antibody discovery and development for use in advanced diagnostic tests. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 4.25M -1.95M 10.17M -10.3M
Total Cashflows From Investing Activities -26.42M -26.42M -3.52M -35.38M
Net Borrowings -4.16M 180M 180M 3M
Total Cash From Financing Activities -10.24M 1.34B 1.94B 271.35M
Change To Operating Activities -160.19M -65.53M -64.26M 122.27M
Issuance Of Stock 1.35B 1.35B 1.77B 268.34M
Net Income -1.53B -1.4B -1.29B -1.48B
Change In Cash -1.7B -222.54M 580.34M -895.33M
Effect Of Exchange Rate
Total Cash From Operating Activities -1.69B -1.54B -1.36B -1.13B
Depreciation 7.02M 4.84M 3.7M 2.96M
Change To Account Receivables 1.41M -52.83M 38.36M 31.32M
Other Cashflows From Financing Activities -4.36M -4.36M -5.94M 1k
Change To Netincome 2.73M 3.15M -31.68M 172.15M
Capital Expenditures

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 1.23B 1.3B 1.16B 1.31B
Income Before Tax -1.53B -1.4B -1.29B -1.47B
Net Income -1.53B -1.4B -1.29B -1.48B
Selling General Administrative 420.06M 387.52M 372.31M 444.59M
Gross Profit 111.28M 284.65M 245.27M 422.46M
Ebit -1.54B -1.4B -1.28B -1.33B
Operating Income -1.54B -1.4B -1.28B -1.33B
Interest Expense -967k -967k -967k -1.32M
Income Tax Expense 2.42M 2.42M 3.24M 13.49M
Total Revenue 212.85M 447.58M 480.85M 712.93M
Cost Of Revenue 101.57M 162.93M 235.58M 290.47M
Total Other Income ExpenseNet 8.04M 538k -6.94M -132.08M
Net Income From Continuing Ops -1.53B -1.4B -1.29B -1.48B
Net Income Applicable To Common Shares -1.53B -1.4B -1.29B -1.48B

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 154.47M 186.58M 384.59M 446.39M
Total Stockholder Equity 2.68B 2.62B 3.11B 1.89B
Other Current Liabilities 54.17M 93.3M 85.92M 135.27M
Total Assets 2.83B 2.81B 3.49B 2.34B
Common Stock 5.45B 6.13B 1.39B 1.52B
Other Current Assets 127M 218.01M 323.6M 270.87M
Retained Earnings -2.81B -3.53B 1.69B 342.02M
Treasury Stock 28M 21.73M 28.63M 35.1M
Cash 2.33B 2.11B 2.69B 1.79B
Total Current Liabilities 113.44M 145.13M 342.71M 392.54M
Other Stockholder Equity 28.29M 22.02M 28.92M 35.4M
Property, Plant, and Equipment 15.95M 11.11M 7.16M 4.2M
Total Current Assets 2.61B 2.56B 3.25B 2.22B
Net Tangible Assets 2.68B 2.62B 3.11B 1.89B
Net Receivables 77.43M 130.83M 114.35M 61.51M
Accounts Payable 31.89M 29.94M 40.11M 29.81M


Insider Transactions

Here are the insider transactions of stock shares related to CHIOME BIOSCIENCE INC:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to CHIOME BIOSCIENCE INC. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on CHIOME BIOSCIENCE INC

Here is the result of two systematic investment strategies applied to CHIOME BIOSCIENCE INC. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on CHIOME BIOSCIENCE INC

The following chart shows the equity curve of the two systematic investment strategies applied to CHIOME BIOSCIENCE INC:

CHIOME BIOSCIENCE INC automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -15.52% on the backtest period.

Performance at glance

Performance

-15.52 %

Latent gain

-452.0 ¥

Invested capital

2912.0 ¥

Annualized return

-3.7 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on CHIOME BIOSCIENCE INC

This is the result of two momentum investment strategies applied to CHIOME BIOSCIENCE INC. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on CHIOME BIOSCIENCE INC

The following chart shows all the entries opened by the momentum investment system on CHIOME BIOSCIENCE INC:

CHIOME BIOSCIENCE INC momentum entries
  • The first momentum investment strategy would give -6.52% of return on CHIOME BIOSCIENCE INC. That represents -326.0¥ of latent gain with 5000.0¥ of employed capital.
  • The second momentum investment strategy would give 1.77% of return on CHIOME BIOSCIENCE INC. That represents 64.0¥ of latent gain with 3626.0¥ of employed capital.
Performance at glance (1Q Momentum)

Performance

-6.52 %

Latent gain

-326.0 ¥

Invested capital

5000.0 ¥

Annualized return

18.59 %
Performance at glance (2Q Momentum)

Performance

1.77 %

Latent gain

64.0 ¥

Invested capital

3626.0 ¥

Annualized return

0.48 %

Momentum equity curve on CHIOME BIOSCIENCE INC

The following chart shows the equity curve of the two momentum strategies applied to CHIOME BIOSCIENCE INC:

CHIOME BIOSCIENCE INC momentum equity

Note: the dividends potentially given by CHIOME BIOSCIENCE INC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on CHIOME BIOSCIENCE INC

The following chart shows the employed capital evolution of the two momentum strategies on CHIOME BIOSCIENCE INC since the beginning:

CHIOME BIOSCIENCE INC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250¥, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000¥.


Buy the dip strategy result on CHIOME BIOSCIENCE INC

Buy the dip entry openings on CHIOME BIOSCIENCE INC

CHIOME BIOSCIENCE INC

The performance achieved by the robo-advisor on CHIOME BIOSCIENCE INC is 40.89%. That represents 357.0$ of latent gain with 873.0¥ of employed capital. The following chart shows CHIOME BIOSCIENCE INC stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of CHIOME BIOSCIENCE INC, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

40.89 %

Latent gain

357.0 ¥

Invested capital

873.0 ¥

Annualized return

18.59 %

Equity curve of the strategy applied to CHIOME BIOSCIENCE INC

The following chart shows the result of the investment strategy applied to CHIOME BIOSCIENCE INC:

CHIOME BIOSCIENCE INC

Note: the dividends potentially given by CHIOME BIOSCIENCE INC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on CHIOME BIOSCIENCE INC

The following chart shows the employed capital evolution since the beginning of the investment strategy on CHIOME BIOSCIENCE INC:

CHIOME BIOSCIENCE INC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on CHIOME BIOSCIENCE INC

In this section, I will compare the three previous investment strategies applied to CHIOME BIOSCIENCE INC.

Equity curve comparison on CHIOME BIOSCIENCE INC

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

CHIOME BIOSCIENCE INC investment strategy comparison

Employed capital comparison on CHIOME BIOSCIENCE INC

CHIOME BIOSCIENCE INC investment comparison

Performance comparison on CHIOME BIOSCIENCE INC

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -15.52% -452.0¥ 2912.0¥ -3.7%
Momentum 1 quarter -6.52% -326.0¥ 5000.0¥ -1.65%
Momentum 2 quarters 1.77% 64.0¥ 3626.0¥ 0.48%
Non-directional 40.89% 357.0¥ 873.0¥ 18.59%
Annualized return comparison

Automatic investment

-3.7 %

Momentum 1Q

0.48 %

Momentum 2Q

0.48 %

Non-directional

18.59 %

Correlated stocks

Here are the most positively and negatively correlated stocks with CHIOME BIOSCIENCE INC:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between CHIOME BIOSCIENCE INC and the other stocks. There may be false positives or some missing correlated stocks. If the price of CHIOME BIOSCIENCE INC does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name CHIOME BIOSCIENCE INC
Country Japan
City Tokyo
Address Sumitomo-Fudosan Nishi-shinjuku building
Phone 81 3 6383 3561
Website www.chiome.co.jp
FullTime employees
Industry Biotechnology
Sector Healthcare
Exchange XTKS
Ticker 4583.XTKS
Market www.jpx.co.jp

CHIOME BIOSCIENCE INC ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown